Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that it has entered into a definitive agreement to acquire Purigen Biosystems, Inc. (Purigen), a company that develops and commercializes automated nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology, which was licensed exclusively from Stanford and developed by Purigen. Purigen's ITP technology is a solution-based purification approach and therefore different from protocols in routine use today, which tend to rely on binding to a matrix, washing and then removal from the matrix. Those protocols are less efficient at capturing molecules from dilute solutions or from samples with small amounts of cells and often result in shorter average lengths of DNA than what optical genome mapping (OGM) requires. The transaction is expected to accelerate the adoption of OGM due to anticipated improvements in its ultra high molecular weight (UHMW) DNA sample preparation workflow.

Bionano Genomics to Acquire Purigen Biosystems to Enable Further Simplified and Accelerated DNA Isolation for Optical Genome Mapping (OGM) and Address Difficult Sample Types in New Applications with Isotachophoresis (ITP) on the Ionic Purification System

VAALCO Energy

GoPro

Many people have trouble deciding where to invest their money. There are so many options, but it can be difficult to decide which one of them is the best.

3 Penny Stocks You Can Count On in This Uncertain Market

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing optical genome mapping (OGM) to detect structural variants (SVs) and balanced rearrangements relevant to prostate cancer (PCa) pathogenesis. OGM identified SVs in all samples, potentially improving the success rate for finding pathogenic variants and streamlining the detection process.

Publication Shows Utility of OGM in Solid Tumor Research with Study on Detection of Complex Genomic Rearrangements in Prostate Cancer

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs.

Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

Tilray Brands

These low-priced equities could explode higher soon.

2 Penny Stocks That Could Make You Filthy Rich

JinkoSolar Holding

Schrodinger 

During the current earnings season, a few of the companies whose stocks I own delivered great third-quarter results. These results, along with their other achievements, shows that the firms' technologies are being widely-embraced by end users.

3 Hypergrowth Stocks That Will Make You a Millionaire by 2027

Amyris

Canopy Growth

FuelCell Energy

Hall of Fame Resort & Entertainment

Meta Materials

B2Gold

It may seem a little crazy to talk about finding cheap penny stocks to buy at this time. The economy is cooling, and even blue-chip stocks are struggling to gain traction.

7 Cheap Penny Stocks to Buy Before They Pop Off

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano Genomics Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded.

Bionano Genomics, Inc. (BNGO) Q3 2022 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 8.33% and 7.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates

–  55% year-over-year revenue growth in Q3 2022

Bionano Genomics Reports Third Quarter 2022 Financial Results and Highlights Recent Business Progress

Ocugen, Inc.

Tesla

Select analysts and pundits foresee game-changing upside from this fast-paced trio.

3 High-Octane Growth Stocks With 357% to 571% Upside, According to Wall Street

Enphase Energy

Elbit Systems

Illumina

ServiceNow

ON Semiconductor

Shockwave Medical

It's true that the troika of Microsoft (NASDAQ: MSFT ), Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), and Meta (NASDAQ: META ), much loved by the Street for the decade that ended in mid-2021, reported disappointing third-quarter results. Once viewed as beyond reproach by most, those three stocks are now being shunned and scorned by the “smart money.

Ranking 7 Top Tech Stocks to Buy From Biggest to Smallest

SAN DIEGO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the Association for Molecular Pathology (AMP) Annual Meeting and Expo 2022 with a broad range of content covering optical genome mapping's (OGM) utility for research applications including prenatal and postnatal analysis, genetic disease and hematological malignancies.

Bionano Genomics Announces Extensive Lineup of Content at Association for Molecular Pathology (AMP) Annual Meeting Featuring OGM Utility Across Broad Range of Research Applications

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, November 3, 2022 at 4:30 p.m. Eastern Time to report financial results for the third quarter 2022 and to highlight recent corporate progress.

Bionano Genomics to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast on November 3, 2022

Bionano's stock price movements have little to do with its successes.

Wall Street Is Still Bullish on This Punished Growth Stock -- Is It a Buy?

Bionano Genomics (NASDAQ: BNGO ) stock is rising higher on Wednesday after providing an update on its Long String VANTAGE product. This is a system that handles “automated, high throughput isolation of ultra high molecular weight (UHMW) DNA.

What Is Going on With Bionano Genomics (BNGO) Stock Today?

SAN DIEGO and RENO, Nev., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Hamilton and Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the Long String VANTAGE, a system for automated, high throughput isolation of ultra high molecular weight (UHMW) DNA for use in optical genome mapping (OGM) is commercially available. The Long String VANTAGE is the result of collaborative development from the companies and features new and innovative tools and consumables used for consistent, high-quality UHMW DNA extraction using human blood samples. The Long String VANTAGE is expected to begin shipping in Q1 2023.

Hamilton and Bionano Genomics Announce Commercial Availability of World's First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM

On an up day for Wall Street, the genome-mapping company may have benefited from a short squeeze.

Why Bionano Genomics' Shares Spiked 16.42% on Tuesday

SAN DIEGO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a peer-reviewed study evaluating optical genome mapping (OGM) as a method for investigating abnormal noninvasive prenatal testing (NIPT) results because of its ability to accurately identify complex structural aberrations relevant to recurrent pregnancy loss and infertility.

OGM Evaluated as a Method for Investigating Abnormal NIPT Results due to its Ability to Detect Chromosomal Structural Variations Found in Recurrent Pregnancy Loss

Source: Dennis Diatel / Shutterstock.com Bionano Genomics (NASDAQ: BNGO ) stock is rising higher on Wednesday following the publication of a study related to optical genome mapping (OGM). According to the company, OGM was used to investigate a molecular subgroup of hepatocellular carcinoma ( HCC ).

Why Is Bionano Genomics (BNGO) Stock Up 11% Today?

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study showing the use of optical genome mapping (OGM) to investigate a molecular subgroup of hepatocellular carcinoma (HCC), which is the most common form of liver cancer, in order to explore the complex structural variations (SVs) induced by replication stress. In this study, OGM helped unravel replication stress-induced events, which may cause or contribute to genomic instability in cancer cells, potentially leading to the activation of oncogenes and disruption of tumor suppressors.

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing that WGS Identified only 63% of Structural Variations that OGM Detected in Liver Cancer

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano's optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories' first OGM-based laboratory developed test (LDT). Bionano Laboratories recently received CLIA-certification for its lab in San Diego. This certification will enable Bionano Laboratories to offer services to customers seeking to implement OGM into their diagnostic routines and for research applications with hospitals, pharmaceutical companies, and other parties that may desire a more robust regulatory structure for their projects.

Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories, and Expands its Clinical Testing Menu with Launch of First OGM-Based LDT for FSHD

Air Industries Group

Denison Mines

Gran Tierra Energy

Vizsla Silver Corp

If your initial instinct is that penny stocks represent extraordinarily risky ideas that feature little chance for success, you would be 100% correct. Clearly, conservative or risk-averse investors will find this subsegment of the market anathema to their approach.

7 Penny Stocks to Buy Now for Extraordinary Gains

SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing OGM to detect cryptic balanced chromosomal rearrangements (BCRs) found in subjects who experienced recurrent pregnancy loss (RPL). Compared to traditional cytogenetic methods, OGM successfully identified cryptic reciprocal translocation in all samples, improving the success rate for finding pathogenic variants of cryptic BCRs and streamlining the process of detection.

Bionano Genomics Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss

SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study evaluating the performance of OGM for detection of cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) samples. This work is the second independent study, following a recent publication from researchers at MD Anderson Cancer Center, showing that OGM enables better molecular characterization of MDS. This paper extends that research to AML and the findings indicate that OGM may have an even greater impact on the characterization of AML compared to MDS, which led the researchers to recommend integrating OGM into new prognostic scoring methods for both myeloid malignancies.

News for Bionano Genomics Stock (BNGO)